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Frontotemporal dementia (FTD) is the second most common early-onset dementia. A rare 
mutation in CHMP2B gene was found to be associated with FTD linked to chromosome 3. 
Previous studies have shown that mutant CHMP2B could lead to impaired autophagy 
pathway and altered RNA metabolism. However, it is still unknown what genes mediate the 
crosstalk between different pathways affected by mutant CHMP2B. Genetic screens designed 
to identify genes interacting with mutant CHMP2B represents a key approach in solving the 
puzzle. Expression of mutant CHMP2B (CHMP2Bintron5) in Drosophila eyes leads to a 
neurodegenerative phenotype including melanin deposition and disrupted internal structure 
of ommatidia. The phenotype is easily quantified by estimating the percentage of black dots 
on the surface of the eyes. Using this established Drosophila model, I searched for genes 
encoding RNA binding proteins that genetically modify CHMP2Bintron5 toxicity. I found that 
partial loss of Pumilio, a translation repressor, mitigates CHMP2Bintron5 induced toxicity in 
the fly eyes. Western blot analysis showed that down regulation of Pumilio does not 
significantly decrease CHMP2Bintron5 protein level, indicating indirect regulation involved in 
suppression of the phenotype. The molecular targets regulated by Pumilio and the 
mechanism underlying CHMP2Bintron5 toxicity suppression by Pumilio down-regulation 
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Chapter 1.1 FTD-ALS: RNA metabolism vs. Protein homeostasis 
Frontotemporal dementia (FTD) is a progressive neurodegenerative disease with complex 
genetic basis (1). It is characterized by atrophy of frontal and/or temporal lobe resulting in 
changes in personality and social behavior (1). FTD overlaps with amyotrophic lateral 
sclerosis (ALS), a motor neuron degenerative disease with C9ORF72 intronic GGGGCC 
repeat expansion being the most common mutation in both diseases (2). Sequestration of 
RNA binding proteins (RBPs) by repeat expansion leading to disrupted RNA metabolism is 
one of the possible pathogenic mechanisms for C9ORF72 FTD/ALS (2). In other FTD cases 
without C9ORF72 mutations, aggregation of misfolded RNA binding proteins is also a 
prevalent hallmark (3). More than 50% of the FTD patients show pathological neuronal 
inclusions positive for either TDP-43 (45%) or fused in sarcoma (FUS) (9%) (2), and rare 
mutations in these RNA binding proteins were also found in FTD patients (2). Thus, 
defective RNA metabolism is a major pathological mechanism in FTD and related disorders. 
On the other hand, FTD can also be caused by mutations in several genes related to the 
autophagy pathway, such as the ESCRT-III component charged multivesicular body protein 
2B (CHMP2B), AAA-ATPase member valosin-containing protein (VCP), ubiquitin-like 
protein ubiquilin-2 (UBQLN2), and most recently TBK1 (2, 4). Both VCP and UBQLN2 show 
TDP-43 pathology (5, 6). Knocking down TDP-43 will decrease mRNA level of major 
autophagy gene Atg7 (7). It remains unknown how genetic mutations in distinct molecular 
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pathways such as RNA metabolism and autophagy can cause the same disease. Nor do we 
understand whether these molecular pathways interact with each other in FTD. 
Chapter 1.2 CHMP2B mutation associated with FTD-3 
The study of CHMP2B mutations can bring insights into the interplay between RNA 
metabolism and protein homeostasis in FTD-ALS. The Danish CHMP2B mutation is caused 
by a G-to-C transition in the acceptor splice site of exon 6 (8). The mutation leads to 
replacement of the C-terminal 36 amino acids by either a single valine (CHMP2Bintron5), or 
29 amino acids (CHMP2BD10) (8) (Figure 1.1). CHMP2BD10 is expressed at lower level than 
CHMP2Bintron5 and is not considered the major toxic form of mutant CHMP2B(9). CHMP2B 
is a component of the ESCRT-III complex, which is formed transiently on the limiting 
membrane of early endosomes to promote biogenesis of multivesicular bodies (MVBs) (10). 
Previous work from our lab and others show that CHMP2B functions redundantly with its 
paralog CHMP2A and knocking down CHMP2B has no effect on neuronal cell survival (11). 
CHMP2Bintron5 toxicity arises from disrupting interaction with Vps4 and preventing 
dissociation of ESCRT-III complex from the membrane (11). More importantly, transient 
overexpression of CHMP2Bintron5 causes the accumulation of abnormal autophagosomes in 
mammalian neurons (11). One genetic screen from our lab identified Syntaxin 13 as a strong 
genetic modifier of CHMP2Bintron5 and that Syntaxin 13 plays a novel role in autophagosome 
maturation, further highlighting the role of autophagy in FTD pathogenesis (12). On the other 
hand, our lab found that miR-124 but not miR-9 was downregulated in CHMP2Bintron5 
transgenic mouse model (13). MVBs were also found to associate with components of 
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miRNA effector complex and regulate miRNA activity (14). However, how CHMP2Bintron5 
might regulate the miRNA pathway remains to be determined. 
 
Figure 1.1 Location of Danish CHMP2B mutation and the resulting transcript (from (8)).  
Chapter 1.3 Animal models of mutant CHMP2B toxicity  
Development of animal model is essential to understand the mechanism by which mutant 
CHMP2B leads to relevant phenotypes. CHMP2Bintron5 is the major form of mutant CHMP2B 
protein for its higher stability and toxicity (11). Model systems of CHMP2Bintron5 mutation 
range from in vitro models including primary cultured neurons and human cell lines, to in 
vivo models like Drosophila and mice. Here we took the advantage of Drosophila genetics as 
a tool to identify genes that interact with CHMP2Bintron5. UAS transgenic flies expressing 
CHMP2BWT and CHMP2Bintron5 were generated and recombined with GMR-Gal4 to drive 
the expression specifically in photoreceptor neurons. CHMP2Bintron5 expression leads to 
deposition of melanin on the surface of eyes as well as disrupted internal structure of 
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ommatidia (15) (Figure 1.2). Accumulation of autophagosomes was also observed in fly eyes 
by over-expression of CHMP2Bintron5 or knock down of the ESCRT-III subunit Shrub (Figure 
1.3) (11). 
 
Figure 1.2 CHMP2BIntron5 expression lead to severe degeneration in Drosophila eye. C, F: 






Figure 1.3 Accumulation of autophagosomes in fly eyes (electron microscopy, red 
arrows). The expression of CHMP2Bintron5 and shrub RNAi was driven by the GMR-





Chapter 2. Material and methods 
Chapter 2.1 Fly Stocks 
D.melanogaster strains were raised at 25C on standard food with yeast diet. Lines 
containing GMR-Gal4 and UAS-CHMP2Bintron5 (or UAS-CHMP2BWT) were recombined 
as described before (15). RNAi lines for the genetic screen were ordered from the Vienna 
Drosophila Resource Center. Pumilio mutant line (#3260) was ordered from the 
Bloomington Drosophila Stock Center. Pumilio RNAi line (#v101399) was used to 
confirm the genetic suppression. UAS-Pumilio (on X chromosome) was obtained from 
the Jan Lab. Atg5 inverted repeat line (#F003001) was ordered from Fly ORF. The RNAi 
line targeting GFP was crossed with GMR-CHMP2Bintron5 as a UAS control for the 
genetic screen. To quantify the eye phenotype, we classified it into 3 classes from high 
(very strong, large area of black dots), medium (considerably strong, medium area of 
black dots) and low (weak, little black dots). Representative pictures are displayed in 
Figure 2.1. Genetic interactions were evaluated according to the percentage of each class 
in F1 progeny.   
Chapter 2.2 Western blots 
Rabbit CHMP2B antibody that recognizes both CHMP2BWT and CHMP2Bintron5 was 
reported as described in the previous publication (15). To extract total proteins, ~30 fly heads 
were homogenized in lysis buffer and ~10µg of protein was separated on 12% SDS gel, 
blotted onto PVDF membrane and probed with primary antibody against CHMP2B (1:1000, 
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developed in the Gao lab) or beta-actin (1:1000, cell signaling technology, #4967S) and 
secondary antibody (1:5000, goat anti-rabbit HRP).  
 
 
Figure 2.1 Representative images of the Drosophila eye phenotype severity in each 
classification group. Images show eye phenotype induced by CHMP2Bintron5 expression, 














Chapter 3.1 A genetic screen identifies modifiers of CHMP2Bintron5 
CHMP2Bintron5 phenotypes are sensitive to partial loss of other genetic factors (15). To 
identify genes that genetically interact with mutant CHMP2B, genome-wide screens using 
deficiency lines were conducted which resulted in the discovery of several modifier genes 
including Serpin5 (15)，Syntaxin13 (12) and Rab8 (16). This collection of deficiency lines 
cover 75% of the Drosophila genome(15). Although very useful, deficiency screens lack 
precision and can create added-up effects. Moreover, haploinsufficiency by 50% 
downregulation may not be enough for some affected genes to exert an effect. On the other 
hand, RNA interference, based on sequence complementation between the siRNA and the 
target RNA, is relatively specific. Its knockdown efficiency of gene expression can reach 
more than 50%. Therefore, RNAi screens are a complementary way to identify additional 
genes that could have been missed by deficiency screens. Since our focus is on RNA 
metabolism affected by mutant CHMP2B and RNA binding proteins play important 
regulatory roles, Dr. Dejun Yang initiated a screen with RNAi lines targeting genes encoding 
all Drosophila RNA binding proteins. Together we identified a number of RNA binding 
proteins as genetic modifiers of CHMP2B toxicity (Figure 3.1) from a total of 547 RNAi 
lines covering 338 unique genes encoding RNA binding proteins. RNAi lines of 18 different 
genes showed potential enhancement effect (more severe eye phenotype than expressing 





Figure 3.2 A. Both Pumilio RNAi and loss of function mutant suppress CHMP2Bintron5 eye 
phenotype, as summarized in the histogram. The difference between control group and RNAi 
or mutant group is significant (Chi-square test, p-value < 0.0001). B. Representative image of 
the eye surface from Pumilio overexpression line shows the disrupted eye structure. In 
contrast, the Pumilio mutant line has normal eyes comparable to wild type line.  
Pumilio is a member of an evolutionally conserved family of RNA binding proteins 
characterized by Pumilio-Homology domain (Pum-HD) (19). Pumilio represses translation of 
hunchback (hb) mRNA in the posterior of Drosophila embryo and the regulation depends on 
two bipartite nanos-responsive elements (NRE) in the 3’ UTR of hb mRNA (20). Pumilio 
binds to the NRE and recruits Nos and Brat, forming a RNA-protein complex that leads to hb 
mRNA deadenylation and translation repression (21). Pumilio’s role as translation repressor 
was also confirmed in post-mitotic neurons, which affected both neuronal development and 
function. Pumilio mutant impairs development of peripheral sensory neurons into multi-
dendritic cells and several Pumilio alleles were found to affect long-term memory formation 
in adult flies (22) (23). Its mammalian homolog Pumilio1 was recently found to regulate 
ATAXIN1 levels in mice, suggesting that Pumilio1 haploinsufficiency could contribute to 
human neurodegeneration (24). Pumilio1 mutant mice were significantly smaller in body size 
and developed progressive motor deficits (Figure 3.3)(24). On the other hand, down 
regulation of Pumilio expression was found to suppress neurodegenerative-associated 
phenotype in our CHMP2Bintron5 fly model. This highlights the complexity of the role played 
by Pumilio in neurodegenerative diseases and calls for further investigation into the 




Figure 3.4 Left: Western blot with antibody against CHMP2B-intron5 and beta-actin. Right: 
Quantification of western blot (intron5 level normalized over beta-actin), no statistically 
significant difference was detected between control and RNAi or mutant lines (one-way 
ANOVA). 
Chapter 3.4 Pumilio targets and downstream pathways 
A previous study identified mRNAs that associated with Pumilio using transgenic flies 
expressing affinity-tagged Pumilio by DNA microarrays (25). 714 Pumilio targets were 
found in adult flies and 165 are in embryos with an overlap of 31 genes (25). In adult flies, 
the target mRNAs of Pumilio showed general increases in transcript abundance compared to 
non-target transcripts, indicating that Pumilio might lead to accelerated target mRNA 
degradation (Figure 4.1) (25). Since the eye phenotype of CHMP2Bintorn5 fly is more of a 
developmental defect, the embryonic target genes of Pumilio are of greater interest to us. 
Autophagy gene Atg5 is one of the Pumilio embryonic targets. We anticipated that the Atg5 
mRNA level would increase in Pumilio mutant or knock down flies and down regulation of 
Atg5 would enhance CHMP2Bintron5 eye phenotype. Our preliminary data from a genetic 
interaction experiment supports this scenario (Figure 3.6).  The change in Atg5 transcript 
level could be further consolidated by quantification of Atg5 mRNA and protein level in 
Pumilio mutant flies. In addition, the biophysical interaction between Pumilio and Atg5 
mRNA could be examined by performing electrophoretic mobility shift assays. Autophagy 
pathway is one of the pathways affected by CHMP2Bintron5 mutation (11). If a member of the 




Chapter 4.  DISCUSSIONS 
 
Previous studies showed that mutant CHMP2B affects RNA metabolism. In this study, we 
identified several RNA binding proteins as genetic modifiers of CHMP2Bintron5 toxicity, 
indicating that regulation of RNA metabolism could also modify mutant CHMP2B 
phenotype. We further confirmed Pumilio as a strong suppressor. The suppression could be 
due to direct regulation of CHMP2Bintron5 protein level, or indirect regulation of downstream 
pathways. Our data support the latter one. The autophagy related gene Atg5 is one of the 
downstream targets of Pumilio regulation according to a DNA microarray analysis (25). The 
genetic interaction between Atg5 and CHMP2Bintron5 indicates that Pumilio downregulation 
may suppress CHMP2Bintron5 phenotype by up regulation of Atg5. The possibility that 
Pumilio could regulate autophagy pathway would further strengthened the links between 
RNA metabolism and protein homeostasis, the converging mechanism in FTD-ALS.  
However, it remains to be addressed whether the hypothesized regulatory role of Pumilio in 
flies is conserved in mammalian systems. Pumilo mutant or RNAi suppresses 
neurodegenerative phenotype caused by CHMP2Bintron5 in fly eyes, whereas partial loss of 
Pumilio1 exacerbates SCA1-like neurodegeneration(24). Therefore, it would be necessary to 
test the interaction between Pumilio and CHMP2Bintron5 in mammalian systems, both in vitro 
and in vivo. We anticipate that in cell lines expressing CHMP2Bintron5 and forebrain neurons 
of transgenic mice expressing CHMP2Bintron5 under the control of tetracycline promoter, 
there will be an increase in expression levels and possible change in subcellular distribution 
of Pumilio. Furthermore, downregulation of Pumilio may be developed into a therapeutic 




Table 1. List of candidate RNAi lines for genetic screen 
Screen # CG # VDRC # Targeted Gene Name 
1 CG3373 1278GD  Hmu Hemomucin 
2 CG13425 2912GD  bl bancal 
3 CG5393 4289GD  apt apontic 
4 CG43113 5158GD  orb2 also CG43782 
5 CG6203 8933GD  Fmr1 
 6 CG31716 10850GD  Cnot4 Cnot 4 homologue 
7 CG6222 10853GD  su(s) suppressor of sable 




12031GD  Ref1 
RNA and export factor binding 
protein 1 
10 CG10293 13756GD  how held out wings 




16040GD  Hrb27C 
Heterogeneous nuclear 






4 lethal (1) G0004 
14 CG10711 16846GD  Vps36 Vacuolar protein sorting 36 
15 CG32721 17038GD  NELF-B 
 16 CG11726 17544GD  CG11726 
 17 CG11726 17545GD  CG11726 
 18 CG14506 17684GD  CG14506 
 19 CG1691 20321GD  Imp IGF-II mRNA-binding protein 
20 CG2910 20942GD  nito spenito 
21 CG2931 20946GD  CG2931 
 22 CG5994 21009GD  Nelf-E Negative elongation factor E 
23 CG17136 21083GD  Rbp1 RNA-binding protein 1 
24 CG3162 21379GD  LS2 Large Subunit 2 
25 CG4760 21536GD  bol boule 
26 CG3949 21752GD  hoip hoi-polloi 
27 CG4051 21779GD  egl egalitarian 
28 CG34354 21949GD  CG34354 
 29 CG5263 22044GD  smg smaug 
30 CG5655 22186GD  Rsf1 Repressor splicing factor 1 




32 CG6937 22315GD  CG6937 
 33 CG10302 22837GD  bsf bicoid stability factor 
34 CG10466 23368GD  CG10466 
 35 CG8021 23675GD  CG8021 
 36 CG1316 23851GD  CG1316 
 37 CG5728 24696GD  CG5728 
 38 CG3312 24742GD  Rnp4F RNA-binding protein 4F 
39 CG14628 24889GD  CG14628 
 40 CG6049 25497GD  barc barricade 
41 CG3294 26110GD  CG3294 
 42 CG3594 26246GD  Eap Exu-associated protein 
43 CG3691 26270GD  Pof Painting of fourth 
44 CG3613 26332GD  qkr58E-1 quaking related 58E-1 
45 CG4119 26395GD  CG4119 
 46 CG4266 26472GD  CG4266 
 47 CG4806 26633GD  CG4806 
 48 CG9346 27013GD  CG9346 
 49 CG5654 27472GD  yps ypsilon schachtel 
50 CG5720 27487GD  Nab2 
 51 CG6605 27683GD  BicD Bicaudal D 
52 CG7804 28068GD  CG7804 
 53 CG9218 28117GD  sm smooth 
54 CG5422 28649GD  Rox8 
 55 CG8636 28937GD  CG8636 
 56 CG32562 28996GD  xmas-2 




29523GD  Hrb98DE 
Heterogeneous nuclear 
ribonucleoprotein at 98DE 
59 CG10203 31203GD  x16 
 60 CG10948 31388GD  CG10948 
 61 CG13298 31777GD  CG13298 
 62 CG1340 32192GD  CG1340 




32829GD  Ref2 
RNA and export factor binding 
protein 2 
65 CG17838 33011GD  Syp Syncrip 
66 CG1954 33434GD  Pkc98E Protein C kinase 98E 
67 CG31000 33735GD  heph hephaestus 
68 CG32062 34046GD  A2bp1 Ataxin-2 binding protein 1 
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69 CG4429 34301GD  Rbp2 RNA-binding protein 2 
70 CG33522 34426GD  scaf6 
 71 CG3808 34713GD  CG3808 
 72 CG5215 34969GD  Zn72D Zinc-finger protein at 72D 




37583GD  Dp1 
Dodeca-satellite-binding 
protein 1 
75 CG5821 37850GD  qkr58E-2 quaking related 58E-2 




38377GD  TBPH 
TAR DNA-binding protein-43 
homolog 




38988GD  APC4 
Anaphase Promoting Complex 
subunit 4 




39725GD  PQBP1 
Poly-glutamine tract binding 
protein 1 
82 CG6227 40351GD  CG6227 
 83 CG3780 40471GD  Spx Spliceosomal protein on the X 
84 CG5442 40590GD  SC35 
 85 CG4824 42004GD  BicC Bicaudal C 




42175GD  NiPp1 
Nuclear inhibitor of Protein 
phosphatase 1 
88 CG9984 42217GD  TH1 
 89 CG11886 42971GD  Slbp Stem-loop binding protein 
90 CG5213 43450GD  CG5213 
 91 CG5589 44322GD  CG5589 
 92 CG9373 44658GD  rump rumpelstiltskin 
93 CG11454 45116GD  CG11454 
 94 CG3689 45278GD  CG3689 
 95 CG9143 46330GD  CG9143 
 96 CG14230 46902GD  CG14230 
 97 CG10279 46908GD  Rm62 
 98 CG14414 48176GD  CG14414 
 99 CG4896 48197GD  CG4896 
 100 CG4396 48891GD  fne found in neurons 
101 CG1034 48966GD  bcd bicoid 
102 CG4887 49022GD  CG4887 
 103 CG5893 49549GD  D Dichaete 
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51759GD  Hrb87F 
Heterogeneous nuclear 
ribonucleoprotein at 87F 
106 CG16788 51851GD  RnpS1 RNA-binding protein S1 
107 CG4612 52497GD  CG4612 
 108 CG3460 52672GD  Nmd3 Nonsense-mediated mRNA 3 
109 CG9373 100001KK  rump rumpelstiltskin 
110 CG9984 100009KK  TH1 
 111 CG33522 100199KK  scaf6 
 112 CG10203 100226KK  x16 
 113 CG3373 100286KK  Hmu Hemomucin 




100381KK  PQBP1 
Poly-glutamine tract binding 
protein 1 
116 CG3691 100546KK  Pof Painting of fourth 
117 CG5422 100563KK  Rox8 




100732KK  Hrb87F 
Heterogeneous nuclear 
ribonucleoprotein at 87F 
120 CG10293 100775KK  how held out wings 
121 CG11886 100785KK  Slbp Stem-loop binding protein 
122 CG10128 100805KK  tra2 transformer 2 
123 CG4429 100817KK  Rbp2 RNA-binding protein 2 
124 CG3151 101412KK  Rbp9 RNA-binding protein 9 
125 CG4760 101435KK  bol boule 
126 CG4396 101508KK  fne found in neurons 
127 CG8376 101511KK  ap apterous 
128 CG31184 101528KK  LSm3 




101555KK  Hrb27C 
Heterogeneous nuclear 
ribonucleoprotein at 27C 
131 CG10328 101567KK  nonA-l nonA-like 
132 CG4070 101765KK  Tis11 Tis11 homolog 
133 CG3056 101781KK  ssx sister-of-Sex-lethal 
134 CG6354 102159KK  Rb97D Ribonuclear protein at 97D 
135 CG3429 102368KK  swa swallow 
136 CG12478 102442KK  bru-3 bruno-3 
137 CG34354 102597KK  CG34354 
 138 CG1340 102825KK  CG1340 




140 CG43081 103427KK  vas vasa 
141 CG5393 103665KK apt apontic 
142 CG6937 103728KK  CG6937 
 143 CG5808 103789KK  CG5808 
 144 CG14414 103952KK  CG14414 
 145 CG14230 104096KK  CG14230 
 146 CG4051 104141KK  egl egalitarian 
147 CG32562 104156KK  xmas-2 
 148 CG1034 104160KK  bcd bicoid 
149 CG4528 104334KK  snf sans fille 




104401KK  TBPH 
TAR DNA-binding protein-43 
homolog 




104471KK  Ref1 
RNA and export factor binding 
protein 1 
154 CG10466 104715KK  CG10466 
 155 CG43065 104949KK  bru-2 bruno-2 
156 CG5442 104978KK  SC35 
 157 CG1316 105148KK  CG1316 
 158 CG13425 105271KK  bl bancal 
159 CG4887 105322KK  CG4887 
 160 CG8636 105325KK  CG8636 
 161 CG3689 105499KK  CG3689 




105585KK  Ref2 
RNA and export factor binding 
protein 2 
164 CG3460 105619KK  Nmd3 Nonsense-mediated mRNA 3 
165 CG13298 105704KK  CG13298 
 166 CG14838 105707KK  CG14838 
 167 CG9143 105825KK  CG9143 
 168 CG14506 105907KK  CG14506 




106047KK  Dp1 
Dodeca-satellite-binding 
protein 1 
171 CG5874 106245KK  Nelf-A Negative elongation factor A 
172 CG7903 106475KK  CG7903 
 173 CG3949 106496KK  hoip hoi-polloi 
174 CG42458 106608KK  CG42458 
 175 CG5753 106645KK  stau staufen 
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176 CG4119 106696KK  CG4119 
 177 CG3594 106734KK  Eap Exu-associated protein 
178 CG4896 106762KK  CG4896 
 179 CG5821 106944KK  qkr58E-2 quaking related 58E-2 
180 CG10881 106972KK  CG10881 
 181 CG30122 106984KK  CG30122 
 182 CG6049 107013KK  barc barricade 
183 CG3312 107063KK  Rnp4F RNA-binding protein 4F 
184 CG7185 107147KK  CG7185 
 185 CG5893 107194KK  D Dichaete 
186 CG3780 107304KK  Spx Spliceosomal protein on the X 
187 CG8781 107385KK  tsu tsunagi 
188 CG10711 107417KK  Vps36 Vacuolar protein sorting 36 
189 CG8205 107575KK  fus fusilli 
190 CG1794 107888KK  Mmp2 Matrix metalloproteinase 2 
191 CG16788 107953KK  RnpS1 RNA-binding protein S1 
192 CG6695 107965KK  CG6695 
 193 CG42458 108072KK  CG42458 
 194 CG6605 108084KK  BicD Bicaudal D 
195 CG9218 108351KK  sm smooth 
196 CG5589 108642KK  CG5589 
 197 CG3808 108653KK  CG3808 




108859KK  NiPp1 
Nuclear inhibitor of Protein 
phosphatase 1 
200 CG8614 108950KK  Neos Neosin 
201 CG2910 109436KK  nito spenito 
202 CG7804 109689KK  CG7804 
 203 CG43065 109739KK  bru-2 bruno-2 
204 CG9412 109911KK  rin rasputin 
205 CG17136 110008KK  Rbp1 RNA-binding protein 1 
206 CG5263 110207KK  smg smaug 
207 CG11094 110306KK  dsx doublesex 
208 CG10948 110357KK  CG10948 
 209 CG31716 110472KK  Cnot4 Cnot 4 homologue 
210 CG14641 110507KK  CG14641 
 211 CG32062 110518KK  A2bp1 Ataxin-2 binding protein 1 
212 CG5720 110710KK  Nab2 
 213 CG31000 110749KK  heph hephaestus 
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214 CG6227 110778KK  CG6227 
 215 CG7082 2554GD  papi 




12031GD  Ref1 
RNA and export factor binding 
protein 1 
218 CG2522 14877GD  Gtp-bp GTP-binding protein 
219 CG11505 15286GD  CG11505 
 220 CG10384 16045GD  CG10384 
 221 CG11109 17528GD  CG11109 
 222 CG11123 18142GD  CG11123 
 223 CG1582 19617GD  CG1582 
 224 CG12924 20280GD  Lsm11 
 225 CG18787 20697GD   CG18787 
 226 CG18789 20699GD  CG18789 




21614GD  Srp72 
Signal recognition particle 
protein 72 
229 CG2950 21763GD  CG2950 
 230 CG4547 21867GD  Atx-1 Ataxin 1 
231 CG4816 21951GD  qkr54B quaking related 54B 
232 CG4849 21962GD  CG4849 
 233 CG5347 22089GD  CG5347 




23569GD  SmE 
Small ribonucleoprotein 
particle protein SmE 
236 CG16807 23843GD  roq roquin 
237 CG33526 25787GD  PNUTS 
 238 CG31957 25926GD  CG31957 
 239 CG5316 25953GD  CG5316 
 240 CG3584 26242GD  qkr58E-3 quaking related 58E-3 
241 CG4810 26637GD  CG4810 
 242 CG34334 27020GD  CG34334 
 243 CG9596 27026GD  CG9596 
 244 CG10803 27318GD  CG10803 
 245 CG7437 28024GD  mub mushroom-body expressed 




31946GD  SmD2 
Small ribonucleoprotein 
particle protein SmD2 
248 CG2253 33057GD  Upf2 
 249 CG6779 37741GD  RpS3 Ribosomal protein S3 
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250 CG2100 38037GD  CG2100 
 251 CG31155 39134GD  Rpb7 
 252 CG9705 40665GD  CG9705 
 253 CG40351 40682GD  Set1 
 254 CG9004 40727GD  CG9004 




43978GD  Srp72 
Signal recognition particle 
protein 72 
257 CG9484 44675GD hyd hyperplastic discs 
258 CG12131 45744GD  Adam 
 259 CG31992 45772GD  gw gawky 




46199GD  Srp54k 
Signal recognition particle 
protein 54k 
262 CG14100 46739GD  CG14100 
 263 CG8241 47782GD  pea peanuts 
264 CG17768 49674GD  CG17768 
 265 CG9099 49895GD  CG9099 
 266 CG1677 50195GD  CG1677 
 267 CG4279 50653GD  LSm1 
 268 CG13690 100017KK  CG13690 
 269 CG31256 100122KK  Brf 
 270 CG8635 100278KK  CG8635 
 271 CG6011 100287KK  Prp18 
 272 CG31426 100304KK  ligatin 
 273 CG31155 100309KK  Rpb7 
 274 CG16725 100392KK  Smn survival motor neuron 




100690KK   SmD2 
Small ribonucleoprotein 
particle protein SmD2 
277 CG4816 100702KK  qkr54B quaking related 54B 
278 CG8443 100709KK  clu clueless 
279 CG11274 100751KK  SRm160 
 280 CG13124 100966KK  CG13124 
 281 CG8276 101090KK   bin3 bicoid-interacting protein 3 
282 CG11123 101297KK  CG11123 
 283 CG5641 101343KK   CG5641 
 284 CG31140 101347KK  CG31140 
 285 CG10851 101740KK  B52 








103560KK   SmD3 
Small ribonucleoprotein 
particle protein SmD3 
289 CG31992 103581KK  gw gawky 
290 CG6694 103643KK  ZC3H3 
 291 CG10228 103710KK  Inr-a Inverse regulator a 
292 CG1664 103715KK  sbr small bristles 
293 CG33158 103751KK   CG33158 
 294 CG6412 103791KK  CG6412 
 295 CG12938 103819KK  Lsm10 
 296 CG8395 103922KK  Rrp42 
 297 CG1898 104327KK  HBS1 
 298 CG4810 104342KK  CG4810 
 299 CG5941 104349KK  CG5941 
 300 CG3642 104351KK  Clp Clipper 




104471KK  Ref1 
RNA and export factor binding 
protein 1 
303 CG4620 104665KK  unk unkempt 
304 CG3019 104716KK  su(wa) suppressor of white-apricot 
305 CG3249 105107KK  spoon spoonbill 
306 CG8778 105442KK  CG8778 
 307 CG33197 105486KK    mbl 
 308 CG7437 105495KK  mub mushroom-body expressed 
309 CG42257 105744KK  Snp Snipper 
310 CG17737 105763KK   CG17737 




105883KK   
Rbp1-
like 
 313 CG10418 105940KK  CG10418 
 314 CG6094 106144 KK  CG6094 
 315 CG9596 106324KK  CG9596 
 316 CG5193 106688KK  TfIIB Transcription factor IIB 




106756KK  Srp19 
Signal recognition particle 
protein 19 
319 CG9425 106833KK  CG9425 
 320 CG33526 106862KK  PNUTS 
 321 CG17018 106964KK  CG17018 
 322 CG1685 106974KK  pen penguin 
		
24	
323 CG2100 107002KK  CG2100 
 324 CG5941 107297KK  CG5941 
 325 CG34362 107503KK  CG34362 
 326 CG4567 107709KK  ico iconoclast 
327 CG12750 107717KK  ncm nucampholin 
328 CG42670 107912KK  ps pasilla 
329 CG42551 107986KK  larp La related protein 




108126KK  SmE 
Small ribonucleoprotein 
particle protein SmE 
332 CG11337 108158KK  CG11337 
 333 CG8335 108169KK  CG8335 
 334 CG18596 108183KK  CG18596 






5 Ribonuclease X25 
337 CG5649 108801KK  kin17 
 338 CG9107 109500KK  CG9107 







 341 CG34334 110116KK  CG34334 
 342 CG6999 110143KK  CG6999 
 343 CG8273 110165KK  CG8273 
 344 CG5347 110427KK  CG5347 




110571KK  Cpsf160 
Cleavage and polyadenylation 
specificity factor 160 
347 CG7035 110673KK  Cbp80 cap binding protein 80 
348 CG42382 10463GD  CG42382 






5 Ribonuclease X25 
351 CG5836 13426GD  SF1 Splicing factor 1 
352 CG6011 13760GD  Prp18 
 353 CG8335 15507GD  CG8335 
 354 CG10473 16052GD  Acn Acinus 
355 CG11337 16422GD  CG11337 
 356 CG12129 17065GD  CG12129 
 357 CG12750 17304GD  ncm nucampholin 
		
25	




18009GD  Cpsf160 
Cleavage and polyadenylation 
specificity factor 160 
360 CG5705 19855GD  CG5705 
 361 CG12085 20144GD  pUf68 poly U binding factor 68kD 
362 CG16941 20338GD  CG16941 
 363 CG31426 21340GD  ligatin 
 364 CG31601 21378GD  CG31601 
 365 CG4043 21776GD  Rrp46 
 366 CG4076 21784GD  Nufip 
 367 CG4709 21923GD  CG4709 








particle U1 subunit C 
370 CG6169 22272GD  Dcp2 Decapping protein 2 




23422GD  Srp14 
Signal recognition particle 
protein 14 
373 CG8778 23621GD  CG8778 
 374 CG9344 23689GD  CG9344 
 375 CG14648 23918GD  lost 
 376 CG8635 24131GD  CG8635 
 377 CG8395 24305GD  Rrp42 
 378 CG30176 25592GD  wibg within bgcn 
379 CG3019 25598GD  su(wa) suppressor of white-apricot 
380 CG32364 26044GD  CG32364 
 381 CG8963 26917GD  CG8963 
 382 CG31140 27193GD  CG31140 
 383 CG6422 27615GD  CG6422 
 384 CG6987 27776GD  SF2 
 385 CG4279 28793GD  LSm1 
 386 CG8273 28887GD  CG8273 
 387 CG8882 28976GD  Trip1 
 388 CG8912 28989GD  Psi P-element somatic inhibitor 
389 CG17737 29216GD  CG17737 




29575GD  Cpsf100 
Cleavage and polyadenylation 
specificity factor 100 
392 CG3927 29674GD  CG3927 






31342GD  SmD1 
Small ribonucleoprotein 
particle protein SmD1 
395 CG10837 31364GD  eIF-4B Eukaryotic initiation factor 4B 
396 CG1664 32691GD  sbr small bristles 
397 CG17018 32810GD  CG17018 
 398 CG7184 34373GD  Mkrn1 Makorin 1 
399 CG31950 34750GD  CG31950 
 400 CG4567 34875GD  ico iconoclast 
401 CG7878 35288GD  CG7878 
  
           402 CG8427 
 
35933GD  SmD3 
Small ribonucleoprotein 
particle protein SmD3 
403 CG7066 36572GD  Sbp2 SECIS-binding protein 2 
404 CG10228 38365GD  Inr-a Inverse regulator a 
405 CG33100 38399GD  4EHP eIF4E-Homologous Protein 
406 CG12938 38754GD  Lsm10 




40587GD  SmB 
Small ribonucleoprotein 
particle protein SmB 
409 CG8443 42136GD  clu clueless 




44344GD  Ssrp 
Structure specific recognition 
protein 
412 CG9323 44984GD  CG9323 
 413 CG5605 45027GD  eRF1 eukaryotic release factor 1 
414 CG16725 45447GD  Smn survival motor neuron 
415 CG9609 47605GD  CG9609 
 416 CG33158 47737GD  CG33158 
 417 CG3249 48005GD  spoon spoonbill 
418 CG5641 48200GD  CG5641 
 419 CG6094 48721GD  CG6094 
 420 CG30100 48945GD  CG30100 
 421 CG32708 49325GD  CG32708 
 422 CG18497 49542GD  spen split ends 
423 CG18259 50094GD  CG18259 
 424 CG10418 50245GD  CG10418 
 425 CG12357 50876GD  Cbp20 cap binding protein 20 
426 CG33714 51019GD  CG33714 
 427 CG4602 51088GD  Srp54 
 428 CG16940 51854GD  CG16940 








Signal recognition particle 
protein 9 
431 CG7138 101288KK  r2d2 
 432 CG7184 101694KK  Mkrn1 Makorin 1 
433 CG14891 102118KK  CG14891 
 434 CG12493 102360KK  CG12493 
 435 CG34362 102523KK  CG34362 
 436 CG5334 102765KK  CG5334 




104867KK  Srp68 
Signal recognition particle 
protein 68 
439 CG10384 104941KK  CG10384 
 440 CG6169 105130KK  Dcp2 Decapping protein 2 
441 CG8912 105135KK  Psi P-element somatic inhibitor 
442 CG4900 105583KK  Irp-1A Iron regulatory protein 1A 




105682KK  Srp9 
Signal recognition particle 
protein 9 
445 CG11505 105949KK  CG11505 
 446 CG10084 105950KK  swm second mitotic wave missing 
447 CG10306 105991KK  CG10306 
 448 CG6382 106240KK  Elf Ef1α-like factor 
449 CG10868 106257KK  orb oo18 RNA-binding protein 
450 CG6779 106321KK  RpS3 Ribosomal protein S3 
451 CG10803 106599KK  CG10803 
 452 CG6610 106830KK  CG6610 
 453 CG12357 107112KK  Cbp20 cap binding protein 20 
454 CG16941 107162KK  CG16941 
 455 CG42768 107183KK  Msp-300 Muscle-specific protein 300 




107644KK  SmF 
Small ribonucleoprotein 
particle protein SmF 
458 CG32708 107827KK  CG32708 
 459 CG7006 108205KK  CG7006 
 460 CG12924 108336KK  Lsm11 
 461 CG5316 108346KK  CG5316 
 462 CG4547 108396KK  Atx-1 Ataxin 1 
463 CG4849 108597KK  CG4849 
 464 CG42670 108666KK  ps pasilla 




466 CG18497 108828KK  spen split ends 








particle U1 subunit C 
469 CG42768 109023KK  Msp-300 Muscle-specific protein 300 
470 CG32706 109212KK  CG32706 
 471 CG1677 109697KK  CG1677 
 472 CG6961 109951KK  CG6961 
 473 CG18787 109955KK  CG18787 
 474 CG18823 110023KK  CG18823 
 475 CG5263 110207KK  smg smaug 




110284KK  Srp54k 
Signal recognition particle 
protein 54k 
478 CG9323 110410KK  CG9323 
 479 CG15481 110412KK  Ski6 
 480 CG32344 110441KK  CG32344 




110713KK  SmB 
Small ribonucleoprotein 
particle protein SmB 
483 CG14648 110736KK  lost 
 484 CG31957 110758KK  CG31957 
 485 CG4620 4267GD  unk unkempt 
486 CG1147 9605GD  NPFR1 neuropeptide F receptor 
487 CG10993 16166GD  CG10993 
 488 CG32344 21675GD  CG32344 
 489 CG6122 22235GD  piwi 
 490 CG6143 22245GD  Pep Protein on ecdysone puffs 
491 CG13277 23862GD  LSm7 
 492 CG13690 24648GD  CG13690 
 493 CG3642 26259GD  Clp Clipper 
494 CG3688 26269GD  l(2)35Bd lethal (2) 35Bd 
495 CG3931 26310GD  Rrp4 
 496 CG7138 26727GD  r2d2 




27351GD  Srp68 
Signal recognition particle 
protein 68 
499 CG18178 29264GD  CG18178 
 500 CG16785 30214GD  fz3 frizzled 3 
501 CG42569 31635GD  Larp7 La related protein 7 
		
29	
502 CG13472 32193GD  CG13472 
 503 CG15481 32612GD  Ski6 




33396GD  mask 
multiple ankyrin repeats single 
KH domain 
506 CG1898 33419GD  HBS1 
 507 CG42257 33706GD  Snp Snipper 
508 CG3508 34632GD  Hexim HEXIM ortholog 
509 CG17768 34752GD  CG17768 
 510 CG6413 35090GD  Dis3 
 511 CG6961 35152GD  CG6961 
 512 CG10084 38336GD  swm second mitotic wave missing 
513 CG11360 38491GD  CG11360 




39255GD  SmG 
Small ribonucleoprotein 
particle protein SmG 
516 CG13163 39785GD  CG13163 
 517 CG18596 41675GD  CG18596 
 518 CG6999 41828GD  CG6999 
 519 CG4021 41974GD  CG4021 
 520 CG4973 42016GD  CG4973 
 521 CG30100 43236GD  CG30100 
 522 CG6412 44327GD  CG6412 
 523 CG31156 44479GD  CG31156 
 524 CG18811 45295GD  Capr Caprin 
525 CG5642 46592GD  CG5642 
 526 CG6745 46746GD  CG6745 
 527 CG12493 49836GD  CG12493 
 528 CG4021 52380GD  CG4021 
 529 CG16940 100322KK  CG16940 
 530 CG7971 101384KK  CG7971 




101444KK  Srp14 
Signal recognition particle 
protein 14 
533 CG3931 102375KK  Rrp4 




103411KK  mask 
multiple ankyrin repeats single 
KH domain 
536 CG7082 103708KK  papi 




538 CG7066 106169KK  Sbp2 SECIS-binding protein 2 
539 CG6422 106251KK  CG6422 
 540 CG4709 106252KK  CG4709 
 541 CG5642 107267KK  CG5642 
 542 CG31156 107269KK  CG31156 
 543 CG1147 107663KK  NPFR1 neuropeptide F receptor 
544 CG5705 108376KK  CG5705 
 545 CG42382 109862KK  CG42382 
 546 CG12131 110514KK  Adam 
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